Technology guiding future directions in CLL
Current research to overcome T-cell dysfunction in CLL and improve therapies
Why venetoclax is a promising new drug for CLL
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
ASH 2015 highlights by Prof. Michael Hallek